Transcript Clayton Overview Presentation

Alexandra Richardson, PhD, CLP
July 2016
Clayton Biotechnologies, Inc. is a for-profit company which facilitates
the commercialization of medical discoveries made by the Clayton
Foundation for Research and its supporting entities.
The Clayton Foundation for Research is a nonprofit medical
research organization in Houston, Texas established in 1933 by
Benjamin Clayton.
The two-fold mission of the Foundation is to:
► conduct medical research for the purpose of discovering the cause,
prevention and cure of diseases for the benefit of mankind, and
► transfer the resulting medical research discoveries from the laboratory to
the use of the general public by patenting and licensing such technology
for development into drugs or other products.
2
Medical Research at Leading Research Institutions
North Carolina State
U. of Geneva
UCSD
Salk
UT-Austin
UTHSC-San Antonio
3
UT-Southwestern
MD Anderson
UT-Medical Branch
Baylor College of Medicine
Medical research for the purpose of
discovering the cause, prevention and
cure of diseases for the benefit of mankind
Medical Research to Develop Cures
Cancer
Immunotoxins for targeted cancer therapy
CNS &
Ophthalmology
Stem Cell Therapy for Parkinson’s Disease
Avicin to treat Mantle cell Lymphoma
Monoclonal antibodies targeting angiogenesis
Engineered proteases
Next generation anti-mitotic drugs
Metabolic
Diseases
Urocortin peptides and gene therapy for
diabetes
Modulation of brain stress in neurological
diseases
Genetic disease models for neurological
diseases
GLP-1 combination therapy
Gene therapy and peptide therapeutics for
AMD
Fc engineered aglycosylated antibodies
Molecular switches in glucose control
Novel therapeutic strategies for liver cancer
4
Early detection and treatment of glaucoma
Medical Research to Develop Cures
Infectious Diseases
Vaccines for Zika, Dengue and
Chinkungunya
Autoimmune &
Inflammation
Cardiology
Engineered proteases
Urocortin peptides and gene therapy
for congestive heart failure
Fc engineering of aglycosylated
antibodies
OCT-TPL diagnostics of human
vascular plaques to predict heart
attacks and strokes
Vaccines and diagnostics for
Ehrlichioses
Drug discovery program to hostbased antiviral targets
5
Leaders in Innovation and Technology
Drug Delivery
Examples
Gene
Therapy
Neuropeptides
Protein Engineering,
Antibodies and
Immunotoxins
6
Transforming Research Into Products
Mission Two:
To transfer the resulting medical research discoveries from the
laboratory to the use of the general public by patenting and licensing
such technology for development into drugs or other products.
• Collaborations
• Spin-out companies
• Licensing
7
Portfolio of Start-up Companies
8
Some of Our Other Licensees
9
Marketed Products
Exparel
DepoDur
• Morphine liposome injectable suspension
• Post-operative pain
Depocyt
• Cytarabine liposomes injectable suspension
• Lymphomatous and solid tumor meningitis
Attrius
Retcam
AccuPlex 4
SCA6 Diagnostic tests
FIA
10
• bupivacaine liposome injectable suspension
• Pain
• Cardiac PET Imaging
• Medical imaging systems for private practices
• Neonatal and pediatric imaging system
• Wide-field digital imaging system for the hospital and clinic
• Ehrlichoisis canine
• Assay for canine vector borne diseases
• Ataxia diagnostic
• Assay for Spinocerebellar ataxia type 6 (SCA6)
• Functional Intracellular analysis
• Assay for intracellular function of essential micronutrients
Clinical Pipeline
Candidate
compound
11
Indication
Partner
Development Stage
Lenti-D
Childhood
ALD
Pre-clinical
Phase I
LentiGlobin
Betathalassemia
Pre-clinical
Phase I/II
LentiGlobin
Sickle cell
anemia
Pre-clinical
Phase I
Retinostat
AMD
Pre-clinical
Phase I
Urocortin
Congestive
Heart Failure
Pre-clinical
Phase I
VC-01
Type I
Diabetes
Pre-clinical
Phase I
a-TEA
Breast cancer
Pre-clinical
Phase I
Phase II/III
Phase II
Available to Partner
Advanced Pre-clinical Pipeline
Candidate
compound
12
Indication
Development Stage
Encorstat
Corneal
graft
rejection
Pre-clinical
Avicin
Mantle Cell
Lymphoma
Pre-clinical
Dengue tetra
vaccine
Dengue
Fever
Chik vaccine
Chikungunya
VEGF-rGel
Solid
Tumors
VEGF-rGel
AMD
Partner
IND
IND
IND package
Available to Partner
Pre-IND
Available to Partner
IND package
Advanced
pre-clinical
Available to Partner
Available to Partner
Collaboration and Licensing Opportunities
Vaccines and
Anti-Infectives
• Zika, Chik and
Dengue Vaccines
• Vaccines and
Diagnostics for
Ehrlichioses
• Wnt inhibitors for
treatment of
Ehrlichia
• HDAC inhibitors for
treatment of TB,
anthrax, pertussis
and cholera
13
Oncology
• Cripto antagonist
for Cancer
• Granzyme B - a
potent payload for
antibody drug
conjugates (ADC)
• YESS engineering of
proteases
• Fc engineered
antibodies with
specific effector
function
Metabolic
Diseases
• Urocortins and
analogues for
Diabetes
• GLP-1 agonist
combination
therapies for
Diabetes
CNS and
Ophthalmology
• TEAD gene and
peptide therapies
for ocular
neovascular
disease
• CRFR1 antagonists
- therapeutic for
early onset AD
• Stem cell therapy
program for
Parkinson's
Disease
Other Indications
and Technologies
• Filaggrin to treat
dermatological
disorders
• OCT guided laser
knife for surgery in
small spaces
Conducting and funding research
Transferring research into products
One Riverway, Suite 1520
Houston, Texas 77056
713.963.5860
www.claytonbiotech.com
[email protected]